Russia’s Vector State Research Center of Virology and Biotechnology has received more than 45 inquiries from foreign countries for tests and possible production of its anti-coronavirus vaccine, Epivaccorona, the Center’s director, Rinat Maksyutov said on Sunday, TASS informed.
“We have more than 45 inquiries from abroad, from various funds and government organizations, which want to test our vaccine or raise the issue of its production in their countries to ensure security of their citizens,” he said in an interview with the Vestin Nedeli weekly news roundup on the Rossiya-1 television channel.
Russia’s sanitary watchdog said earlier the first and second phases of Epivaccorona’s clinical tests demonstrated its 100-percent immunological efficacy. The vaccine was registered on October 14, 2020.
